TransMedics Group (TMDX)
(Delayed Data from NSDQ)
$168.06 USD
+1.41 (0.85%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $168.81 +0.75 (0.45%) 7:58 PM ET
1-Strong Buy of 5 1
F Value A Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$168.06 USD
+1.41 (0.85%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $168.81 +0.75 (0.45%) 7:58 PM ET
1-Strong Buy of 5 1
F Value A Growth B Momentum C VGM
Zacks News
Labcorp (LH) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Labcorp (LH) is anticipated to drive growth in the first quarter of 2024 through base business expansion, integrating acquisitions and partnerships and advancing in science and technology.
TransMedics (TMDX) Flat As Market Sinks: What You Should Know
by Zacks Equity Research
TransMedics (TMDX) reachead $91.82 at the closing of the latest trading day, reflecting no change compared to its last close.
Quest Diagnostics (DGX) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Acquisitions and partnerships with health plans are expected to drive Quest Diagnostics' (DGX) base business performance in the first quarter of 2024.
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Buy 5 Medical Devices Stocks for a Stable Portfolio in 2024
by Nalak Das
We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These are: AORT, TMDX, DXCM, SWAV, EW.
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XHE
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
Strength Seen in Edwards Lifesciences (EW): Can Its 6.2% Jump Turn into More Strength?
by Zacks Equity Research
Edwards Lifesciences (EW) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Why TransMedics (TMDX) Stock Might be a Great Pick
by Zacks Equity Research
TransMedics (TMDX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Here's What Key Metrics Tell Us About TransMedics (TMDX) Q3 Earnings
by Zacks Equity Research
The headline numbers for TransMedics (TMDX) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Accelerate Diagnostics (AXDX) Moves 12.7% Higher: Will This Strength Last?
by Zacks Equity Research
Accelerate Diagnostics (AXDX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
TransMedics (TMDX) Acquires Summit Aviation for Organ Transplant
by Zacks Equity Research
TransMedics' (TMDX) acquisition of Summit Aviation is likely to help establish TransMedics Aviation, the first integrated national provider of air logistics dedicated exclusively to organ transplantation.
TransMedics (TMDX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
TransMedics (TMDX) delivered earnings and revenue surprises of 80% and 25.52%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Paragon 28, Inc. (FNA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Paragon 28, Inc. (FNA) delivered earnings and revenue surprises of -44.44% and 2.10%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Ekso Bionics (EKSO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ekso Bionics (EKSO) delivered earnings and revenue surprises of -10.71% and 8.12%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
TransMedics (TMDX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
TransMedics (TMDX) delivered earnings and revenue surprises of 68% and 19.72%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Tandem Diabetes Care, Inc. (TNDM) Q1 Earnings Expected to Decline
by Zacks Equity Research
Tandem Diabetes Care, Inc. (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TransMedics (TMDX) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
TransMedics (TMDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in TransMedics (TMDX): Can Its 12.3% Jump Turn into More Strength?
by Zacks Equity Research
TransMedics (TMDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
TransMedics (TMDX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
TransMedics (TMDX) delivered earnings and revenue surprises of 25% and 28.76%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
5 Winning Medical Product Stocks That Still Have Room to Run
by Indrajit Bandyopadhyay
Despite ongoing macro challenges, medical product stocks like Cardinal Health (CAH), TransMedics Group (TMDX), Olink Holding (OLK), Silk Road Medical (SILK) and Neuronetics (STIM) are likely to gain from strong fundamentals.
3 Medical Stocks Creating Wealth Despite Macro Challenges
by Indrajit Bandyopadhyay
Here we discuss three stocks - CAH, LNTH and TMDX - that have been creating wealth for their investors in 2022 as several competitors faltered amid macro challenges. Will the trend continue?
Is Esperion Therapeutics (ESPR) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Esperion Therapeutics (ESPR) and TransMedics (TMDX) have performed compared to their sector so far this year.
TransMedics (TMDX) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does TransMedics (TMDX) have what it takes to be a top stock pick for momentum investors? Let's find out.
TransMedics (TMDX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
TransMedics (TMDX) delivered earnings and revenue surprises of 37.50% and 35.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?